25Aug 2017

IMMUNOHISTOCHEMICAL EXPRESSION OF CYCLIN D1 AND KI 67 IN PREMALIGNANT AND MALIGNANT PROSTATIC LESIONS.

  • Department of Pathology, Faculty of Medicine, Cairo University? and Fayoum University, Egypt.
Crossref Cited-by Linking logo

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Background: Prostatic carcinoma is a common and growing public health problem.Cyclin D1 is an amino acid that is expressed in the cell cycle and that has an important role in regulating cancer progression, also, The Ki-67 protein functions as a nuclear antigen that is only expressed in proliferating cells. It is a marker of the growth fraction in malignant tissue. Objectives: to study the expression of Cyclin D1 and Ki-67 in prostatic adenocarcinoma and PIN and correlate their expression with age, preoperative serum PSA and Gleason score. Materials and Methods: A total of 50 cases including 25 cases of prostatic carcinoma, 10 high grade PIN and 15 of BPH (as a control group) were studied. Tumor grade was determined according to Gleason?s grading system. Cyclin D1 and Ki 67 expressions were determined by IHC staining. Results: In cancer Cyclin D1 was expressed in 23 of 25(92%) cases, in PIN it was expressed in 8 of 10 (80%) cases while in BPH it was expressed in only 3 of 15 (20%) cases. Ki 67 was expressed in 20 of 25 (80%) cancer cases, in PIN it was expressed in 7 of 10 (70%) cases while in BPH it was expressed in only 1 of 15 (6.7%) cases. Both Cyclin D1 and Ki 67 were significantly up regulated in cancer cases as compared to BPH cases (P< 0.001). No significant correlation was found between the intensity of Cyclin D1 expression and Gleason score whereas a statistically significant correlation was observed between the intensity of Ki 67 expression and Gleason score (P < 0.001). A statistically significant positive correlation was observed between Cyclin D1 and Ki 67 expression in cancer group, PIN group and BPH group with P value 0.03, 0.001 and 0.04 respectively. Conclusions:Cyclin D1 may be helpful in distinguishing between BPH, PIN and adenocarcinoma of the prostate, while Ki 67 can be applied along with other prostate cancer prognostic factors.

  1. Gupta Veena, Garg Monika, Chaudhry Manish, Singh Sunita, Sen Rajeev, Gill Meenu, Sangwaiya Ashok. Role of cyclin D1 immunoreactivity and AgNOR staining in the evaluation of benign and malignant lesions of the prostate, Prostate Int. 2014;2:90-96.
  2. Dunn MW, Kazer MW. Prostate cancer overview. Semin 2011; 27: 241-250.
  3. Mokhtar N., Gouda I., Adel I. Malignant male genital tumor. In: Cancer pathology registry 2003-2004 and time trend analysis. Mokhtar N, Gouda I, Adel I (eds). El Sheraa. 2007; 94-96.
  4. Cohen RJ, McNeal JE, Baillie T. Patterns of differentiation and proliferation in intraductal carcinoma of the prostate: significance for cancer progression. Prostate. 2000; 43:11-9.
  5. Diehl JA. Cycling to cancer with cyclin D1. Cancer BiolTher. 2002; 1: 226-231.
  6. Fleischmann A, Rocha C, Saxer-Sekulic N, Zlobec I, Sauter G, Thalmann GN. High-level cytoplasmic cyclin D1 expression in lymph node metastases from prostate cancer independently predicts early biochemical failure and death in surgically treated patients. Histopathology. 2011; 58: 781- 789.
  7. ,Gopalan A., Kudahetti S., et al. Ki-67 and outcome in clinically localized prostate cancer: analysis of conservatively treated prostate cancer patients from Trans-Atlantic Prostate Group study. Brit J Cancer. 2009; 1000: 888-893.
  8. Nagao K., Yamamoto Y., Hara T., et al. Ki67 and BUBR1 may discriminate clinically insignificant prostate cancer in the PSA range < 4 ng/ml. Jpn J ClinOnco. 2011; 41: 555-564.
  9. Amin MB., Grignon DJ., Humphrey PA., Srigley JR. Contemporary application of Gleason grading in 18-gauge needle biopsy, transurethral resection and radical prostatectomy specimens. In:Gleason grading of prostate cancer: Amin MB, Grignon DJ, Humphrey PA and Srigley JR (eds). Philadelphia: Lippincott Williams & Wilkins, 2004, 13-60 pp.
  10. Ozbek E., Mirzak B., Ozbek M., Buyukberber S., Davarci M. Cyclin D1 protooncogen expression in prostate cancer. Turkish Journal of Cancer. 2000; 30: 15-21.
  11. RajuBina, Mehrotra Ravi, ?ijordsbakkenGunnvor, Al-Sharabi Ali K., VasstrandEndre N., Ibrahim Salah O. Expression of p53, Cyclin D1 and Ki-67 in Pre-malignant and Malignant Oral Lesions: Association with Clinicopathological Parameters. Anticancer Research. 2005; 25: 4699-4706.
  12. Madani SH, Ameli S, Khazaei S, Kanani M, Izadi B. Frequency of Ki‑67 (MIB‑1) and P53 expressions among patients with prostate cancer. Indian J PatholMicrobiol. 2011; 54:688‑91.
  13. Ueda N., Yamashita M., Kuroda I., Takenaka I. Immunohistological evaluation of the expression of P27 and cyclin D1 in prostatic specimens. Nishinihon J Urol. 2001;63:246-9.
  14. Comstock CE, Revelo MP, Buncher CR, Knudsen KE. Impact of differential cyclin D1 expression and localization in pros?tate cancer. Br J Cancer. 2007; 96:970-9.
  15. Anis Ilia, Hosni HalaNaguib, Darweesh Mohammed F., Abd El RahmanMarwa. Immunohistochemical Expression of Cyclin D1 in Egyptian Patients with Prostatic Carcinoma. World Journal of Medical Sciences. 2013; 8 (4): 306-313.
  16. , Sheehan CE., Ambros RA., Fisher HA., Kaufman, RP., Ross JS. The prognostic significance of p34 and cyclin D1protein expression in prostate adenocarcinoma. Cancer. 1997; 80: 753-763.
  17. Shiraishi T., Watanabe M., Muneyuki T., Nakayama T., Moirita J., Ito H., Kotake T., Yatani R. A clinicopathological study of p53, p21 (WaF1/CIP1) and cyclin D1expression in human prostate cancer. UrologiaInternationalis. 1998; 61: 90-94.
  18. Drobnjak M., Osman I., ScherHI.,Fazzari M. Cardo CC. Overexpression of Cyclin D1 is associated with metastatic cancer to bone. Clinical Cancer Research. 2000; 6: 1891-1895.
  19. Mu?oz E., G?mez F., Paz J.I., Casado I., Silva J.M., Corcuera M.T., Alonso M. J. Ki-67 immunolabeling in pre-malignant lesions and carcinoma of the prostate. Histological correlation and prognostic evaluation, European Journal of Histochemistry. 2003; 2:123-128.
  20. VermaRenuka, Gupta Veena, Singh Jagjeet, Verma Monica, Gupta Gopal, Gupta Sumiti, Sen Rajeev and RalliMegha. Significance of p53 and ki‑67 expression in prostate cancer. Urology Annals; Oct-Dec.2015, Vol. 7 Issue 4, p488.
  21. Sasor A, Wagrowska‑Danilewicz M, Danilewicz M. Ki‑67 antigen and P53 protein expression in benign and malignant prostatic lesions. Immunohistochemical quantitative study. Pol J Pathol. 2000; 51:31‑6.
  22. Nikoleishvili D, Pertia A, Trsintsadze O, Gogokhia N, Managadze L, Chkhotua A. Expression of p27(Kip1), cyclin D3 and Ki67 in BPH, prostate cancer and hormone‑treated prostate cancer cells. IntUrolNephrol. 2008; 40:953‑9.
  23. Rashed HE, Kateb MI, Ragab AA, Shaker SS. Evaluation of minimal prostatecancer in needle biopsy specimens using AMACR (p504s), p63 and Ki‑67. Life Sci. 2012; 9:12‑21.
  24. Feneley MR, Young MP, Chinyama C, Kirby RS, Parkinson MC. Ki‑67 expression in early prostate cancer and associated pathological lesions.JClinPathol. 1996; 49:741‑8.
  25. Aaltomaa S., K?rj? V., Lipponen P., Isotalo T., Kankkunen J-P., Talja M., Mokka R. Expression of Ki-67, Cyclin D1 and Apoptosis Markers Correlated with Survival in Prostate Cancer Patients Treated by Radical Prostatectomy. Anticancer Research. 2006; 26: 4873-4878.

[Samia M. Gabal, MD, Samar A. El Sheikh, M.D.Hala M. El-hanbuli and MDMaram M. Ayoub, M.B. B.Ch. (2017); IMMUNOHISTOCHEMICAL EXPRESSION OF CYCLIN D1 AND KI 67 IN PREMALIGNANT AND MALIGNANT PROSTATIC LESIONS. Int. J. of Adv. Res. 5 (Aug). 1553-1561] (ISSN 2320-5407). www.journalijar.com

Hala M. El hanbuli

DOI:

Article DOI: 10.21474/IJAR01/5215      
DOI URL: https://dx.doi.org/10.21474/IJAR01/5215

Download Full Paper

Download PDF No. of Downloads: 39 | No. of Views: 174